Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

14 Feb 2012
by Tamzin_Furtado

Posted in Action, Announcements, Events, TB News

Innovative Professional Development Resource for Clinical Researchers and More

globalhealthtrials

We would like to share an exciting development in the field of global health, which has been launched in the last six months – an innovative professional membership scheme for tracking the continued professional development of clinical research staff across all types of trials and all regions.

TB R&D Weekly Update: Tailoring TB Treatment Based on Host Genotype?

cell feb2012

This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes. Additional links to TB R&D news are included.

31 Jan 2012
by Working Group

Posted in Action, Announcements, Events, TB News

News from the 21st Stop TB Partnership Coordinating Board Meeting, Bangkok

stop tb

he 21st Stop TB Partnership Coordinating Board retreat and meeting officially started in Bangkok, Thailand, on Sunday, January 29th with the official opening ceremony held yesterday January 30th. Included are some exciting news from the meeting courtesy of Mark Harrington, Executive Director of the Treatment Action Group (TAG).

27 Jan 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

Summary Available! TB Clinical Trials Consultants Meeting

Businesswoman Talking During Meeting

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.

26 Jan 2012
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: SQ109 and PNU Compounds Additive

JAC cover

In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). Additional links to TB R&D news are included.

20 Jan 2012

TB R&D Weekly Update: TDR Tuberculosis Strain Bank

TDR strain bank

This week we highlight an article looking at the TDR Tuberculosis Strain Bank and its utility. Additional links to TB R&D news are included.

Kick TB Campaign: Scoring Big in South Africa and Beyond

soccerballFront-300x290

The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis (TB).

13 Jan 2012

TB R&D Weekly Update: Totally Drug-Resistant TB

bacteria

Over the past couple of weeks there have been much discussion and reporting on totally drug-resistant tuberculosis (TDR-TB) based on reports of new cases in India. Here are links to coverage of TDR-TB in India, excerpt from a response by Dr. Nardell who we interviewed last year, and link to the WHO Fact Sheet on TDR-TB. Additional links to TB R&D News are included.

TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay

avgayweb111380

This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research. Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. Additional TB R&D news links are included.

8 Dec 2011
by Heather_Ignatius

Posted in Action, Announcements, Front Lines of TB R&D, TB News

4th Annual G-FINDER Survey Released

gfinderjpg

Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients–donors must commit to taking them across the finish line.